AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Vertex Pharmaceuticals Incorporated

$518.62 +$66.49 (+14.71%)
NASDAQ · 14 Sep 2026 13:52 UTC
Previous Close
$515.44
Day Range
$516.49$525.29
Year Range
$374.17$560.25
Market Cap
131.63B
AVG Volume
1.42M
Trailing/Forward PE
29.8/24.52
PEG ratio
2.26
Dividend Yield
-
Next Earnings Date
2026-11-02
Primary Exchange
NASDAQUS
Revenue (USD)
01B2B3B4B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q23.33B
26 Q12.99B
25 Q43.23B
25 Q33.08B
25 Q22.96B
25 Q12.77B
24 Q42.91B
24 Q32.77B
24 Q22.65B
24 Q12.69B
Net Income (USD)
-4B-2B02B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q21.1B
26 Q11.03B
25 Q41.19B
25 Q31.08B
25 Q21.03B
25 Q1646.3M
24 Q4913M
24 Q31.05B
24 Q2-3.59B
24 Q11.1B
Operating Income (USD)
-4B-2B02B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q21.25B
26 Q11.14B
25 Q41.3B
25 Q31.19B
25 Q21.15B
25 Q1630.1M
24 Q41.03B
24 Q31.12B
24 Q2-3.51B
24 Q11.14B
EBITDA (USD)
-4B-2B02B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q21.39B
26 Q11.31B
25 Q41.39B
25 Q31.36B
25 Q21.34B
25 Q1781.8M
24 Q41.18B
24 Q31.28B
24 Q2-3.33B
24 Q11.34B
Cash Flows (USD)
-4B-2B02B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q21.01B
26 Q11.29B
25 Q4348.6M
25 Q31.14B
25 Q2927.4M
25 Q1778.2M
24 Q4492M
24 Q31.3B
24 Q2-3.83B
24 Q11.06B
EPS (USD)
-15-10-50524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX EPS (USD) by quarter
PeriodEPS (USD)
26 Q24.31
26 Q14.02
25 Q44.65
25 Q34.2
25 Q23.99
25 Q12.49
24 Q43.5
24 Q34.01
24 Q2-13.92
24 Q14.21
Expenses (USD)
02B4B6BR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q21.69B
26 Q11.59B
25 Q41.61B
25 Q31.58B
25 Q21.55B
25 Q11.42B
24 Q41.47B
24 Q31.32B
24 Q25.86B
24 Q11.46B
Cash & Debt (USD)
05B10B15BCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q27.85B
26 Q17.25B
25 Q46.61B
25 Q36.29B
25 Q26.38B
25 Q16.2B
24 Q46.12B
24 Q36.52B
24 Q25.8B
24 Q110.17B
Debt ratios
-20020406024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Debt ratios by quarter
PeriodDebt ratios
26 Q2-1.08
26 Q1-0.98
25 Q4-0.56
25 Q3-0.96
25 Q2-1.06
25 Q159.66
24 Q4-9
24 Q3-9.31
24 Q2-10.45
24 Q1-1.89
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Margins by quarter
PeriodMargins
26 Q285.33%
26 Q186.85%
25 Q485.56%
25 Q386.52%
25 Q286.25%
25 Q186.9%
24 Q485.46%
24 Q385.84%
24 Q285.94%
24 Q187.25%
Return on Capital
-30%-20%-10%0%10%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Return on Capital by quarter
PeriodReturn on Capital
26 Q25.43%
26 Q15.33%
25 Q46.38%
25 Q36.25%
25 Q26.01%
25 Q13.92%
24 Q45.56%
24 Q36.69%
24 Q2-24.32%
24 Q15.93%
Shares Outstanding
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Shares Outstanding by quarter
PeriodShares Outstanding
26 Q2253.9M
26 Q1254.1M
25 Q4253.9M
25 Q3255.6M
25 Q2256.7M
25 Q1256.9M
24 Q4257.5M
24 Q3258M
24 Q2258.1M
24 Q1258.2M
Book Value Per Share (USD)
02040608024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q279.75
26 Q176.2
25 Q473.52
25 Q367.76
25 Q266.91
25 Q164.21
24 Q463.73
24 Q360.58
24 Q257.24
24 Q171.83
Total Assets (USD)
010B20B30B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
VRTX Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q227.42B
26 Q126.48B
25 Q426.14B
25 Q324.86B
25 Q224.04B
25 Q122.88B
24 Q422.53B
24 Q322.24B
24 Q220.13B
24 Q123.92B
Employee Count
02K4K6K8K2016201720182019202020212022202320242025
VRTX Employee Count by quarter
PeriodEmployee Count
20256.4K
20246.1K
20235.4K
20224.8K
20213.9K
20203.4K
20193K
20182.5K
20172.3K
20162.15K
PE Ratio
2527.53032.535med 29.29Dec 23Mar 24Jul 24Oct 25Feb 26May 26Sep 26
VRTX PE Ratio by quarter
PeriodPE Ratio
Sep 2629.71
Sep 2631.48
Aug 2631.22
Aug 2631.59
Aug 2629.15
Aug 2628.59
Jul 2627.94
Jul 2627.96
Jul 2628.45
Jul 2628.43
Jul 2630.93
Jun 2628.78
Jun 2626.45
Jun 2626.06
Jun 2626.17
May 2626.21
May 2625.45
May 2625.59
May 2625.18
May 2627.23
Apr 2627.64
Apr 2628.34
Apr 2628.02
Apr 2628.18
Mar 2627.81
Mar 2629.16
Mar 2630.14
Mar 2629.33
Feb 2631.91
Feb 2630.63
Feb 2631.57
Feb 2633.24
Jan 2632.68
Jan 2632.58
Jan 2630.7
Jan 2632.26
Jan 2631.45
Dec 2532.19
Dec 2531.73
Dec 2531.44
Dec 2531.68
Nov 2530.16
Nov 2529.68
Nov 2530.4
Nov 2528.48
Oct 2530.03
Oct 2529.74
Oct 2529.41
Oct 2528.78
Oct 2528.46
Sep 2527.22
Sep 2527.04
Sep 2527.84
Sep 2527.95
Aug 2527.59
Aug 2527.88
Aug 2527.72
Aug 2525.87
Jul 2431.81
Jul 2431.58
Jul 2431.4
Jul 2430.49
Jun 2430.11
Jun 2430.11
Jun 2430.88
Jun 2431.03
May 2429.25
May 2429.35
May 2428.6
May 2427.16
May 2428.56
Apr 2428.3
Apr 2428.07
Apr 2428.23
Apr 2428.95
Mar 2429.76
Mar 2429.59
Mar 2429.03
Mar 2429.45
Mar 2430.81
Feb 2430.62
Feb 2430.06
Feb 2431.45
Feb 2431.58
Jan 2431.99
Jan 2432.35
Jan 2432.23
Jan 2430.97
Dec 2330.26
Dec 2330.13
Dec 2330.54
Dec 2326.04
Dec 2326.11
Nov 2326.25
Nov 2326.06
Nov 2327.78
Nov 2328.81
Oct 2327.21
Oct 2327.71
Oct 2328.41
Free Cash Flow Yield
-2%0%2%4%med 2.76%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
VRTX Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 262.9%
Sep 262.74%
Aug 262.76%
Aug 262.73%
Aug 262.96%
Aug 263.01%
Jul 263.06%
Jul 263.06%
Jul 263.01%
Jul 263.01%
Jul 262.77%
Jun 262.97%
Jun 263.23%
Jun 263.28%
Jun 263.27%
May 263.26%
May 263.36%
May 263.34%
May 263.4%
May 262.97%
Apr 262.92%
Apr 262.85%
Apr 262.88%
Apr 262.87%
Mar 262.9%
Mar 262.77%
Mar 262.68%
Mar 262.75%
Feb 262.53%
Feb 262.64%
Feb 262.56%
Feb 262.73%
Jan 262.78%
Jan 262.79%
Jan 262.96%
Jan 262.81%
Jan 262.89%
Dec 252.82%
Dec 252.86%
Dec 252.89%
Dec 252.87%
Nov 253.01%
Nov 253.06%
Nov 252.99%
Nov 253.19%
Oct 253.2%
Oct 253.24%
Oct 253.27%
Oct 253.34%
Oct 253.38%
Sep 253.53%
Sep 253.56%
Sep 253.46%
Sep 253.44%
Aug 253.49%
Aug 253.45%
Aug 253.47%
Aug 253.72%
Aug 25-1.06%
Jul 25-1.04%
Jul 25-1.06%
Jul 25-1.04%
Jul 25-1.07%
Jun 25-1.11%
Jun 25-1.11%
Jun 25-1.08%
Jun 25-1.09%
May 25-1.11%
May 25-1.12%
May 25-1.12%
May 25-1.15%
May 25-0.76%
Apr 25-0.77%
Apr 25-0.78%
Apr 25-0.78%
Apr 25-0.8%
Mar 25-0.77%
Mar 25-0.75%
Mar 25-0.75%
Mar 25-0.78%
Feb 25-0.79%
Feb 25-0.78%
Feb 25-0.83%
Feb 25-1.07%
Jan 25-1.09%
Jan 25-1.14%
Jan 25-1.19%
Jan 25-1.22%
Jan 25-1.23%
Dec 24-1.23%
Dec 24-1.26%
Dec 24-1.08%
Dec 24-1.08%
Nov 24-1.07%
Nov 24-1.11%
Nov 24-1.08%
Nov 24-0.97%
Nov 24-1.12%
Oct 24-1.11%
Oct 24-1.1%
Price to Sales
8101214med 10.09Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
VRTX Price to Sales by quarter
PeriodPrice to Sales
Sep 2610.37
Sep 2610.98
Aug 2610.89
Aug 2611.02
Aug 2610.17
Aug 269.98
Jul 269.89
Jul 269.9
Jul 2610.07
Jul 2610.06
Jul 2610.95
Jun 2610.19
Jun 269.36
Jun 269.23
Jun 269.26
May 269.28
May 269.01
May 269.06
May 268.91
May 268.94
Apr 269.08
Apr 269.31
Apr 269.2
Apr 269.25
Mar 269.13
Mar 269.58
Mar 269.9
Mar 269.63
Feb 2610.48
Feb 2610.06
Feb 2610.37
Feb 2610.42
Jan 2610.25
Jan 2610.21
Jan 269.62
Jan 2610.11
Jan 269.86
Dec 2510.09
Dec 259.95
Dec 259.86
Dec 259.93
Nov 259.45
Nov 259.3
Nov 259.53
Nov 258.93
Oct 259.57
Oct 259.47
Oct 259.37
Oct 259.17
Oct 259.07
Sep 258.67
Sep 258.61
Sep 258.87
Sep 258.9
Aug 258.79
Aug 258.88
Aug 258.83
Aug 258.24
Aug 2510.7
Jul 2510.87
Jul 2510.64
Jul 2510.85
Jul 2510.64
Jun 2510.21
Jun 2510.2
Jun 2510.54
Jun 2510.43
May 2510.23
May 2510.09
May 2510.15
May 259.84
May 2511.71
Apr 2511.54
Apr 2511.43
Apr 2511.32
Apr 2511.09
Mar 2511.52
Mar 2511.76
Mar 2511.8
Mar 2511.41
Feb 2511.21
Feb 2511.32
Feb 2510.73
Feb 2511.4
Jan 2511.21
Jan 2510.68
Jan 2510.25
Jan 259.95
Jan 259.89
Dec 249.93
Dec 249.65
Dec 2411.26
Dec 2411.22
Nov 2411.37
Nov 2410.95
Nov 2411.31
Nov 2412.55
Nov 2411.77
Oct 2411.93
Oct 2412.06
EV/EBITDA
0100200300med 24.26Sep 24Jan 25Apr 25Oct 25Feb 26May 26Sep 26
VRTX EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2622.96
Sep 2624.39
Aug 2624.18
Aug 2624.48
Aug 2622.51
Aug 2622.05
Jul 2621.51
Jul 2621.53
Jul 2621.92
Jul 2621.9
Jul 2623.91
Jun 2622.18
Jun 2620.31
Jun 2620
Jun 2620.09
May 2620.12
May 2619.51
May 2619.62
May 2619.28
May 2621.57
Apr 2621.9
Apr 2622.47
Apr 2622.21
Apr 2622.34
Mar 2622.05
Mar 2623.14
Mar 2623.94
Mar 2623.28
Feb 2625.38
Feb 2624.33
Feb 2625.1
Feb 2625.25
Jan 2624.81
Jan 2624.73
Jan 2623.25
Jan 2624.48
Jan 2623.84
Dec 2524.43
Dec 2524.06
Dec 2523.84
Dec 2524.02
Nov 2522.82
Nov 2522.45
Nov 2523.02
Nov 2521.5
Oct 2522.75
Oct 2522.51
Oct 2522.26
Oct 2521.75
Oct 2521.5
Sep 2520.52
Sep 2520.37
Sep 2521.01
Sep 2521.1
Aug 2520.81
Aug 2521.04
Aug 2520.91
Aug 2519.44
May 25257.12
Apr 25253.24
Apr 25250.73
Apr 25248.13
Apr 25243.04
Mar 25252.63
Mar 25258.21
Mar 25259.05
Mar 25250.3
Feb 25245.78
Feb 25248.14
Feb 25234.74
Feb 25224.58
Jan 25220.77
Jan 25209.77
Jan 25200.99
Jan 25194.79
Jan 25193.57
Dec 24194.4
Dec 24188.67
Dec 24221.79
Dec 24220.98
Nov 24223.98
Nov 24215.43
Nov 24222.77
Nov 24248.21
Nov 24250.99
Oct 24254.64
Oct 24257.58
Oct 24256.86
Oct 24242.21
Sep 24246.41
Sep 24247.55
Sep 24258.89
Sep 24249.26
Aug 24264.73
Aug 24256.6
Aug 24254.46
Aug 24249.51
Aug 24263.94
Jul 2423.65
Jul 2423.46
Price/Operating Cashflow
20253035med 29.34Dec 23Mar 24Jul 24Oct 25Feb 26May 26Sep 26
VRTX Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2630.49
Sep 2632.3
Aug 2632.04
Aug 2632.41
Aug 2629.91
Aug 2629.34
Jul 2628.59
Jul 2628.6
Jul 2629.1
Jul 2629.08
Jul 2631.64
Jun 2629.44
Jun 2627.06
Jun 2626.66
Jun 2626.77
May 2626.82
May 2626.04
May 2626.18
May 2625.76
May 2629.64
Apr 2630.08
Apr 2630.85
Apr 2630.5
Apr 2630.67
Mar 2630.28
Mar 2631.74
Mar 2632.82
Mar 2631.93
Feb 2634.74
Feb 2633.34
Feb 2634.36
Feb 2632.86
Jan 2632.3
Jan 2632.2
Jan 2630.34
Jan 2631.89
Jan 2631.08
Dec 2531.82
Dec 2531.36
Dec 2531.08
Dec 2531.31
Nov 2529.81
Nov 2529.34
Nov 2530.05
Nov 2528.15
Oct 2528.4
Oct 2528.12
Oct 2527.82
Oct 2527.21
Oct 2526.92
Sep 2525.74
Sep 2525.57
Sep 2526.33
Sep 2526.44
Aug 2526.1
Aug 2526.37
Aug 2526.21
Aug 2524.46
Jul 2432.42
Jul 2432.18
Jul 2432
Jul 2431.07
Jun 2430.69
Jun 2430.68
Jun 2431.47
Jun 2431.62
May 2429.81
May 2429.91
May 2429.15
May 2427.68
May 2429.22
Apr 2428.96
Apr 2428.72
Apr 2428.89
Apr 2429.63
Mar 2430.45
Mar 2430.28
Mar 2429.7
Mar 2430.13
Mar 2431.53
Feb 2431.33
Feb 2430.76
Feb 2424.9
Feb 2425.01
Jan 2425.33
Jan 2425.62
Jan 2425.52
Jan 2424.53
Dec 2323.96
Dec 2323.86
Dec 2324.18
Dec 2320.62
Dec 2320.68
Nov 2320.79
Nov 2320.64
Nov 2322
Nov 2323.83
Oct 2322.51
Oct 2322.92
Oct 2323.5
Price to Book
56789med 6.73Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
VRTX Price to Book by quarter
PeriodPrice to Book
Sep 266.46
Sep 266.85
Aug 266.79
Aug 266.87
Aug 266.34
Aug 266.22
Jul 266.26
Jul 266.26
Jul 266.37
Jul 266.37
Jul 266.93
Jun 266.45
Jun 265.93
Jun 265.84
Jun 265.86
May 265.87
May 265.7
May 265.73
May 265.64
May 265.77
Apr 265.85
Apr 266
Apr 265.93
Apr 265.97
Mar 265.89
Mar 266.18
Mar 266.38
Mar 266.21
Feb 266.76
Feb 266.49
Feb 266.69
Feb 267.05
Jan 266.94
Jan 266.91
Jan 266.51
Jan 266.85
Jan 266.67
Dec 256.83
Dec 256.73
Dec 256.67
Dec 256.72
Nov 256.4
Nov 256.3
Nov 256.45
Nov 256.04
Oct 256.36
Oct 256.3
Oct 256.23
Oct 256.09
Oct 256.03
Sep 255.77
Sep 255.73
Sep 255.9
Sep 255.92
Aug 255.84
Aug 255.91
Aug 255.87
Aug 255.48
Aug 257.2
Jul 257.31
Jul 257.16
Jul 257.3
Jul 257.16
Jun 256.87
Jun 256.87
Jun 257.09
Jun 257.02
May 256.88
May 256.79
May 256.83
May 256.62
May 257.86
Apr 257.75
Apr 257.67
Apr 257.6
Apr 257.45
Mar 257.73
Mar 257.9
Mar 257.92
Mar 257.66
Feb 257.53
Feb 257.6
Feb 257.2
Feb 257.75
Jan 257.62
Jan 257.26
Jan 256.97
Jan 256.76
Jan 256.72
Dec 246.75
Dec 246.56
Dec 247.65
Dec 247.63
Nov 247.73
Nov 247.44
Nov 247.69
Nov 248.53
Nov 248.23
Oct 248.34
Oct 248.44
Vertex Pharmaceuticals Incorporated
VRTX
Stockpicker

Video analysis: VRTX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: VRTX

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

fool.com · 14 Sep 2026

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally. Vertex Pharmaceuticals dominates the cystic fibrosis market with exceptionally high net margins and a pristine balance sheet.

Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher

fxempire.com · 11 Sep 2026

Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

seekingalpha.com · 10 Sep 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

seekingalpha.com · 10 Sep 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights

zacks.com · 8 Sep 2026

Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

fool.com · 8 Sep 2026

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

zacks.com · 8 Sep 2026

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Rep. David Taylor discloses 6 new Congressional stock trades

finbold.com · 7 Sep 2026

Rep. David Taylor discloses 6 new Congressional stock trades

Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, and a regional bank.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.